Author Archives: Andrea Lobo

AVT02, an Humira Biosimilar, Approved in Australia to Treat AS

AVT02, a high-concentration and low-volume biosimilar to AbbVie’s Humira (adalimumab), was approved by health regulators in Australia to treat inflammatory disorders such as ankylosing spondylitis (AS). A biosimilar is a biological medicine with a high degree of similarity — in terms of quality, safety, and efficacy —…

Early Anti-TNF Therapy May Raise Risk of Cardiovascular Disease in AS

Early initiation of anti-tumor necrosis factor (TNF) medications may be associated with an increased risk of cardiovascular events in people with ankylosing spondylitis (AS), a study suggests. “We designed the study with the overall hypothesis that the use of TNF inhibitors, which reduce inflammation and thus cardiovascular risk,…